ORIC Pharmaceuticals (ORIC) Expected to Announce Quarterly Earnings on Monday

ORIC Pharmaceuticals (NASDAQ:ORIC) is expected to be posting its quarterly earnings results before the market opens on Monday, March 10th. Analysts expect ORIC Pharmaceuticals to post earnings of ($0.52) per share for the quarter.

ORIC Pharmaceuticals (NASDAQ:ORIC) last released its quarterly earnings data on Tuesday, February 18th. The company reported ($0.51) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.01. On average, analysts expect ORIC Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

ORIC Pharmaceuticals Price Performance

NASDAQ:ORIC opened at $8.00 on Friday. The firm has a market capitalization of $568.22 million, a P/E ratio of -4.40 and a beta of 1.25. ORIC Pharmaceuticals has a 1-year low of $6.33 and a 1-year high of $16.37. The company’s fifty day moving average price is $9.22 and its 200-day moving average price is $9.39.

Analyst Upgrades and Downgrades

Several research firms recently commented on ORIC. Guggenheim restated a “buy” rating on shares of ORIC Pharmaceuticals in a research report on Wednesday, February 26th. HC Wainwright restated a “buy” rating and set a $21.00 price target on shares of ORIC Pharmaceuticals in a research report on Friday, February 21st. Cantor Fitzgerald restated an “overweight” rating on shares of ORIC Pharmaceuticals in a research report on Tuesday, January 14th. JPMorgan Chase & Co. raised their price target on shares of ORIC Pharmaceuticals from $21.00 to $22.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Finally, Wedbush restated an “outperform” rating and set a $20.00 price target on shares of ORIC Pharmaceuticals in a research report on Monday, January 13th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $18.86.

Insider Buying and Selling at ORIC Pharmaceuticals

In other ORIC Pharmaceuticals news, CEO Jacob Chacko sold 24,660 shares of the stock in a transaction on Monday, December 16th. The shares were sold at an average price of $8.28, for a total transaction of $204,184.80. Following the transaction, the chief executive officer now directly owns 778,648 shares of the company’s stock, valued at $6,447,205.44. This trade represents a 3.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Pratik S. Multani sold 8,850 shares of the firm’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $8.28, for a total transaction of $73,278.00. Following the completion of the transaction, the insider now directly owns 46,765 shares in the company, valued at approximately $387,214.20. This represents a 15.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 42,361 shares of company stock valued at $350,749 over the last ninety days. Corporate insiders own 5.55% of the company’s stock.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.